What problem does it solve?
Aging and senescence research requires synthesizing evidence across GWAS catalogs, pathway databases, drug interaction resources, and clinical trial registries, while carefully distinguishing correlative findings from causal evidence. This Skill provides a structured, evidence-graded workflow for investigating aging genes, senescence markers, and senolytic drug candidates without conflating cell-culture results with human genetic evidence.
Core Features & Use Cases
- Hallmarks-Based Classification: Maps genes and queries to the 12 hallmarks of aging (Lopez-Otin et al., Cell 2023) to guide targeted pathway and disease investigation.
- Evidence-Graded Genetic Analysis: Queries Open Genes, GWAS Catalog, OpenTargets, and PubMed to triage longevity genes (APOE, FOXO3, TERT, CDKN2A) with T1-T4 evidence grading.
- Senolytic Drug Discovery: Finds senolytic and geroprotector candidates (dasatinib+quercetin, navitoclax, fisetin, rapamycin) via DGIdb, ChEMBL, and clinical trial searches with clinical status checks.
- Use Case: Ask how CDKN2A relates to aging, and the Skill classifies it under cellular senescence, pulls curated aging evidence from Open Genes, analyzes KEGG pathway hsa04218, checks senolytic drug interactions, and returns an evidence-graded report.
Quick Start
Ask the agent to investigate how the gene FOXO3 relates to human longevity and what senolytic drugs target its pathway.